乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ESC

<乌鸦传媒>ESC Leaders See Hybrid Meetings as the Future

The society is also actively looking eastward for future meetings

<乌鸦传媒>Polypill Proves Its Mettle for Heart Protection Post-MI

Trial affirms benefit of single drug-combo pill compared with usual care in secondary prevention

<乌鸦传媒>No Detrimental Impact on Cognition With Entresto for Heart Failure

Cost may be reason for underutilization, rather than concerns about cognition, expert noted

<乌鸦传媒>DAPT for 1 Month Falls Short in Acute Coronary Syndrome

STOPDAPT-2 ACS results can't match positive findings from earlier trials

<乌鸦传媒>ADT Options for Prostate Cancer Come Out Even for Heart Safety

But low enrollment brought PRONOUNCE trial to an early close

<乌鸦传媒>Continuous Monitoring With Implantable Loop Recorder Finds More Afib

But preventing strokes? That's a different story.

<乌鸦传媒>LAA Occluder Opens Doors to Patients Who Can't Tolerate Blood Thinners Even Briefly

The Amulet IDE trial that led to Amplatzer Amulet's FDA approval

<乌鸦传媒>Can Image-Guided Fibrosis Ablation Help in Persistent Afib?

Targeting fibrosis in afib with minimal fibrotic disease may improve outcomes, says researcher

<乌鸦传媒>Stenting or Surgery for Patients With Carotid Artery Stenosis?

No differences in outcomes seen between groups

<乌鸦传媒>Good Results When Giving Flu Shots to MI Survivors Still in the Hospital

Vaccination prior to discharge linked to heart benefit

<乌鸦传媒>Faster Not Better in Getting Cardiac Arrest Patients to the Cath Lab

Brain injury is the bigger worry for most people, trial finds

<乌鸦传媒>European CVD Prevention Guide Leans on Age Stratification

Update has new risk assessment score but goes easy on blood pressure

<乌鸦传媒>Lower BP Targets Again Affirmed in Major Trial

STEP trial from China shows major benefits in older population

<乌鸦传媒>Nonsteroidal MRA Drug Cuts Risks in Earlier Diabetic Kidney Disease

Urine screening urged after trial shows benefit of treating cases with preserved kidney function

<乌鸦传媒>Mineral Oil Likely Accounts for Some -- But Not All -- of Vascepa's ASCVD Benefit

Danish study fans the flames of REDUCE-IT controversy

<乌鸦传媒>Add FFR to Diagnostic Angiography? Don't Bother

RIPCORD2 gives resounding "no" on all counts

<乌鸦传媒>Polypills Ready for Prime Time in Large Swaths of People, Researchers Say

Question now is how to implement fixed-dose combo therapy in clinical practice

<乌鸦传媒>His Bundle Pacing Stars in European Guidelines

Revised edition could signal coming U.S. recommendations too

<乌鸦传媒>Ablation, CRT Boost Survival in Permanent Afib With Narrow QRS

APAF-CRT trial reinforces the case for expanded CRT indication

<乌鸦传媒>One Month of DAPT Reasonable in Patients at High Bleeding Risk

MASTER DAPT trial included "all-comer HBR population," but results were with one specific stent

<乌鸦传媒>Edoxaban: A Mixed Bag for TAVR Patients Needing Anticoagulation

Weighing positive efficacy data against excess GI bleeds

<乌鸦传媒>Revamped Valve Disease Guideline: Europe Sees Nearly Eye to Eye With U.S.

There is a different approach to deciding the suitability of TAVR, however

<乌鸦传媒>A Familiar Drug Can Keep Early-Stage HCM at Bay

Treatment with valsartan most beneficial when started early?

<乌鸦传媒>Empagliflozin Improves Outcomes in HFpEF Patients

"A major win" for heart failure with preserved ejection fraction, says editorialist

<乌鸦传媒>New Heart Failure Guidelines Released, but Are They Already Out of Date?

Results of EMPEROR-Preserved contradict guidance

<乌鸦传媒>Milder Heart Failure Might Benefit From Implantable Monitors

Randomized trial signals benefit, albeit hampered by the pandemic

<乌鸦传媒>Loop Recorder Often Finds Major Arrhythmias in Risky Group Post MI

Serious events common in group with an LVEF of 36% to 50% and autonomic dysfunction

<乌鸦传媒>Deadly Arrhythmias Less of a Risk for HF Patients on Dapagliflozin

DAPA-HF analysis further explores mechanism of SGLT2 inhibitor's heart benefits

<乌鸦传媒>Heart Failure Again Takes Center Stage at ESC

EMPEROR-Preserved, new guidelines, and more to come

<乌鸦传媒>Kidney Disease No Barrier to Effient Benefit in ACS

Trial analysis supports superiority over ticagrelor regardless of eGFR

<乌鸦传媒>Does Ejection Fraction Matter Anymore?

Experts debate whether familiar metric still has a place in heart failure management

<乌鸦传媒>ESC Offers Sports, Exercise Guide for Heart Disease Patients

Addresses broad spectrum and specific conditions

<乌鸦传媒>'Definitive Data': Continuing ACE/ARB Tx Safe in COVID-19

Randomized trial affirms no harm in mild to moderate coronavirus cases

<乌鸦传媒>REALITY Check: Stricter RBC Transfusion Safe for Anemic MI Patients

Restrictive strategy makes sense for clinical outcomes, costs

<乌鸦传媒>Vascepa Mechanism Becomes Clearer... As Do Vessels

Treatment tied to regression of atherosclerosis in imaging-based EVAPORATE

<乌鸦传媒>Colchicine Scores for CV Secondary Prevention

LoDoCo2 trial finds substantial benefit, but questions linger

<乌鸦传媒>SGLT2 Inhibitor Wows in Chronic Kidney Disease

DAPA-CKD shows fewer renal events, prolonged overall survival

<乌鸦传媒>PARALLAX Trial: Mixed Results With Entresto in HFpEF

No boost in 6-minute walk test, but some heart failure biomarkers did improve

<乌鸦传媒>Antianginal Tx Fails to Make a Difference After Coronary Stenting

Prophylactic trimetazidine doesn't enhance optimal medical therapy

<乌鸦传媒>Aspirin Alone Best Bet for Majority of Post-TAVR Patients

Lessons from DAPT in PCI do not translate to TAVR, researchers find

2